Drug class in one race
CAR-T cell therapy drugs for Multiple Myeloma
2 tracked CAR-T cell therapy drugs in the Multiple Myeloma race. The class explanation lives on the CAR-T cell therapy page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
1 Phase 21 Phase 1
Head-to-head evidence: Hrain anti-BCMA CAR-T vs JY232